The business will operate across multiple areas of the medical cannabis value chain including cultivation, R&D, extraction, brokering and the distribution of pharmaceutical-grade product.

Frontier intends to deploy the most advanced cannabis production and extraction methods into its operations; developing infrastructure strictly in compliance with the highest Government standards.

The business will be operating through three core units, which will focus on the product across three distinct areas.

CULTIVATION of cannabis plants, strain research and development. Export of specialist pharmaceutical-grade medical cannabis products.

EXTRACTION high-quality THC/CBD medical cannabis oil for export. Offtake and Brokering services, packaged products for global supply.

DISTRIBUTION of pharmaceutical-grade medical cannabis products. Manage relationships with Doctors, Physicians and Pharmacists through medical sales reps.

The units can generate revenue independently but are synergistically structured to drive growth and revenue together to maximise short, medium and long-term returns.

The roof brand, ‘Frontier Botanics’ will form the company’s core identity driving an integrated medical cannabis model through internal development, new acquisitions and joint ventures.

Production and Extraction operations will take place in Lesotho, Colombia and the EU while distribution and sales will begin in Germany and the European Union. The business will target niche, high margin products that target specialist conditions.

“Our vision is to be the strategic leader in under represented medical cannabis market segments. Creating meaningful & sustainable treatments for patients & physicians”.